NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev,
MD, PhD to Specialty Clinic Advisory Board
Company Broadens Scientific Expertise with Addition of Mental Health
Expert in Setting Up and Managing Interventional Psychiatric Clinics
Vancouver, B.C. – September 16, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA:
6UF) (“NeonMind'' or the “Company”), an integrated drug development and wellness company focused
on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions,
announced today the appointment of Dr. Roumen Milev, MD, PhD, Clinical Lead of Providence Care
Hospital Interventional Psychiatry to its Specialty Clinics Advisory Board. Providence Care Hospital is one
of Ontario’s leading providers of specialized care in aging, mental health, and rehabilitation and is fully
affiliated with Queen’s University and St. Lawrence College, and an esteemed member of the Council of
Academic Hospitals of Ontario, Canada.
In his role on NeonMind’s Specialty Clinics Advisory Board, Dr. Milev will leverage his vast experience and
success in setting up and managing interventional psychiatry clinics to support NeonMind as it develops
its company -branded, specialty clinics network to enhance access to evidence -backed effective
treatments including ketamine.
Dr. Milev leads the Interventional Psychiatry Clinic at Providence Care Hospital in Kingston, Ontario and
has overseen more than 1,000 patients successfully treated with ketamine and neurostimulation
modalities. He was appointed the Clinical Director of the Mood Disorder Research and Treatment Service
in Kingston in 2001. From 2007 until 2017, he was the Head of the Department of Psychiatry at Queen’s
University. In 2017, he became the Director of Centre for Neuroscience Studies at Queen’s University and
in 2018, he was appointed as Vice President, Medical and Academic Affairs at Providence Care Hospital.
He is the current Executive Chair Elect of the Canadian Network for Mood and Anxiety Treatments
(CANMAT) and an Executive Committee Member of the Canadian Biomarker Integration Network for
Depression (CAN-BIND). He is a Fellow of the Royal College of Psychiatrists (UK), a Distinguished Fellow of
both the Canadian and American Psychiatry Associations, a Fellow of the Royal College of Physicians of
Canada and defended a PhD in Forensic Psychiatry.
Dr. Milev is actively involved in research in depression, bipolar disorder, and other mental disorders with
a strong focus on stigma, sleep architecture, psychopharmacological and neurostimulation treatments as
well as, microbiome manipulation for treatment of mood and anxiety disorders. He is the author and
editor of over 140 peer -reviewed articles and book chapters and has co -authored multiple CANMAT
guidelines for management of patients with Major Depressive Disorder and Bipolar Disorders, the world’s
most cited m ood disorder treatment guidelines as well as CANMAT treatment guidelines including
ketamine and neurostimulation.
“Dr. Milev is a global expert in research of novel treatments for mood and anxiety disorders and brings
unparalleled experience and leadership expertise in interventional psychiatry which will help support the
development and integration of the most successful protocols and treatment modalities for the launch of
our specialty clinics. With the addition of Dr. Milev to the clinics board, NeonMind will be well positioned
to deliver top notch medical services and programs, bringing access to patients and communities in need,”
said Robert Tessarolo, President & CEO of NeonMind.
On the importance of interventional psychiatry, Dr. Milev said, “I am very proud of the work our team at
Providence Care is doing to have successfully set up and operated our Interventional Psychiatry which is
providing important treatment services to patients using ketamine and neurostimulation modalities.
There are many opportunities to expand patients’ access to these highly effective and safe treatments. I
am pleased to be working with NeonMind in developing their network of clinics that is focused on
enhancing access to treatments and bringing them into community healthcare.”
About NeonMind Biosciences Inc.
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of
psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a
medical services division focused on launching specialty mental health clinics that integrate psychedelic
therapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs
targeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at the
serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The
Company’s second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C
receptor, which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind-branded
specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to
address a variety of mental health needs.
For more information on NeonMind, go to www.NeonMindBiosciences.com
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
Investor Relations:
KCSA Strategic Communications
Scott Eckstein/Tim Regan
Tel: 212-896-1210
Media Inquiries:
KCSA Strategic Communications
Annie Graf
Tel: 786-390-2644
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news
release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward- looking information. These
statements relate to future events or NeonMind’s future performance. The use of any of the words "could",
"expect", "believe", "will", "projected", "estimated" and sim ilar expressions and statements relating to
matters that are not historical facts are intended to identify forward- looking information and are based
on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual
future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain
key personnel, and its expectation as to the development of its intellectual property and other steps in its
preclinical and clinical drug development constitute forward -looking information. Actual results and
developments may differ materially from those contemplated by forward- looking information. Readers
are cautioned not to place undue reliance on forward- looking information. The statements made in this
press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly
update or revise any forward-looking information, whether as a result of new information, future events
or otherwise, except as may be expressly required by applicable securities laws.